vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $15.0M, roughly 1.5× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs 41.3%, a 33.8% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
CBK vs NEUP — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $15.0M |
| Net Profit | $9.5M | $11.3M |
| Gross Margin | — | — |
| Operating Margin | — | 79.8% |
| Net Margin | 41.3% | 75.1% |
| Revenue YoY | — | — |
| Net Profit YoY | 9.7% | — |
| EPS (diluted) | $0.69 | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | — | ||
| Q3 25 | $22.8M | — | ||
| Q1 25 | — | $15.0M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | — | ||
| Q3 25 | $9.5M | — | ||
| Q1 25 | — | $11.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 53.8% | — | ||
| Q1 25 | — | 79.8% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | — | ||
| Q3 25 | 41.4% | — | ||
| Q1 25 | — | 75.1% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | — | ||
| Q3 25 | $0.77 | — | ||
| Q1 25 | — | $6.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $17.0M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $26.0M |
| Total Assets | $2.3B | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $154.8M | — | ||
| Q1 25 | — | $17.0M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $245.2M | — | ||
| Q1 25 | — | $26.0M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q1 25 | — | $30.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $11.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $28.0M | — | ||
| Q1 25 | — | $11.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.7% | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q1 25 | — | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
NEUP
Segment breakdown not available.
